Amrubicin for Patients With Platinum-refractory Small-cell Prostate Cancer: Two Case Reports

Kotaro Suzuki; Tomoaki Terakawa; Shiro Kimbara; Masanori Toyoda; Naoe Jimbo; Yuzo Nakano; Hironobu Minami; Masato Fujisawa

doi:10.1016/j.clgc.2019.12.017

Amrubicin for Patients With Platinum-refractory Small-cell Prostate Cancer: Two Case Reports

Clin Genitourin Cancer. 2020 Jun;18(3):e324-e329. doi: 10.1016/j.clgc.2019.12.017. Epub 2020 Jan 7.

Authors

Kotaro Suzuki¹, Tomoaki Terakawa², Shiro Kimbara³, Masanori Toyoda³, Naoe Jimbo⁴, Yuzo Nakano¹, Hironobu Minami³, Masato Fujisawa¹

Affiliations

¹ Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
² Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Electronic address: daatera0804@yahoo.co.jp.
³ Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe, Japan.
⁴ Division of Pathology, Kobe University Graduate School of Medicine, Kobe, Japan.

PMID: 32005612
DOI: 10.1016/j.clgc.2019.12.017

No abstract available

Keywords: Neuroendocrine differentiation; Neuron-specific enolase; Pro-gastrin-releasing peptide; Small-cell carcinoma; Treatment-related neuroendocrine prostate cancer.

Publication types

Case Reports

MeSH terms

Aged
Anthracyclines / therapeutic use*
Antineoplastic Agents / therapeutic use*
Carcinoma, Small Cell / drug therapy*
Carcinoma, Small Cell / pathology
Drug Resistance, Neoplasm / drug effects*
Humans
Male
Middle Aged
Platinum / pharmacology*
Prognosis
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / pathology

Substances

Anthracyclines
Antineoplastic Agents
Platinum
amrubicin